<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684918</url>
  </required_header>
  <id_info>
    <org_study_id>GEM016</org_study_id>
    <nct_id>NCT00684918</nct_id>
  </id_info>
  <brief_title>Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously Untreated Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemin X</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will evaluate the efficacy of obatoclax in older patients with previously&#xD;
      untreated AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Pilot Safety portion of the study will evaluate the safety of obatoclax administered by a&#xD;
      3 hour infusion for 3 days in a row. The Pilot Schedule portion of the study will randomize&#xD;
      16 patients in to one of two cohorts: 1) patients receiving obatoclax administered by a 3&#xD;
      hour infusion for 3 days in a row or 2) patients receiving obatoclax administered by a 24&#xD;
      hour infusion for 3 days in a row. The schedule with the best overall efficacy and safety in&#xD;
      the Pilot Schedule portion of the study will then be utilized in the Phase II portion of the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the rate of morphologic CR after treatment in the obatoclax single-agent therapy in older patients with previously untreated AML.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obatoclax</intervention_name>
    <description>A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>GX15-070MS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed AML&#xD;
&#xD;
          -  No prior chemotherapy for AML (with the exception that the patients enrolled in the&#xD;
             Pilot Safety evaluation may have had 1 prior therapy)&#xD;
&#xD;
          -  Age ≥70 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2&#xD;
&#xD;
          -  Patients must have normal organ function as defined below:&#xD;
&#xD;
               1. Total bilirubin &lt; or = 2 mg/dL unless resulting from hemolysis,&#xD;
&#xD;
               2. Aspartate transaminase (AST [SGOT])/alanine transaminase (ALT [SGPT]) &lt; or = 2.5&#xD;
                  x institutional ULN&#xD;
&#xD;
               3. Creatinine within normal institutional limits, OR creatinine clearance &gt; or = 50&#xD;
                  mL/min/1.73 meters squared for patients with creatinine levels above&#xD;
                  institutional ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received or are receiving any other investigational or commercial&#xD;
             agents or therapies administered with the intent to treat their malignancy (with the&#xD;
             exception that the patients enrolled in the pilot safety evaluation may have had 1&#xD;
             prior therapy)&#xD;
&#xD;
          -  patients with history of allergic reactions attributed to components of the formulated&#xD;
             product (PEG300 and polysorbate 20)&#xD;
&#xD;
          -  patients with history of seizure disorders or central nervous system leukemia&#xD;
&#xD;
          -  patients with uncontrolled, intercurrent illness including, but not limited to,&#xD;
             symptomatic neurological illness; active, uncontrolled, systemic infection considered&#xD;
             opportunistic, life-threatening, or clinically significant at the time of treatment;&#xD;
             symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia;&#xD;
             significant pulmonary disease or hypoxia; or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients receiving combination&#xD;
             anti-retroviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Viallet, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gemin X Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University - Breslin Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital &amp; Health Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute-Clinical Trials Office</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <disposition_first_submitted>August 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 26, 2013</disposition_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML, obatoclax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obatoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

